(INNE)
VONLEROLIZUMAB(INNF)
VONLEROLIZUMAB(INNS)
VONLEROLIZUMAB(SLE)
VONLEROLIZUMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS TNFRSF4 (TUMOR NECROSIS FACTOR RECEPTOR (TNFR) SUPERFAMILY MEMBER 4, ACT35, OX40, CD13CD134)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-447) [HUMANIZED VH (HOMO SAPIENS IGHV1-46*01 (81.20%) -(IGHD) -IGHJ2*01 R120>Q (109)) [8.8.10] (1-117) -HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 (118-215), HINGE (216-230), CH2 (231- 340), CH3 (341-445), CHS (446-447)) (118-447)], (220- 214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (89.50%) - IGKJ1*01) [6.3.9] (1'-107') -HOMO SAPIENS IGKC*01, KM3 (108'-214')]; DIMER (226-226":229-229")-BISDISULFIDE, RECOMMENDED INN: LIST 78(WHO)
VONLEROLIZUMABUM(INN)